Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment.
The clinical and biochemical effects of adjuvant reserpine treatment were investigated in 12 chronic schizophrenic patients on long-term neuroleptic medication. The global severity of the symptoms using the Brief Psychiatric Rating Scale did not change significantly in the whole group, however, a moderate decrease in positive symptoms (factors though disturbance, activation and hostile-suspiciousness) was observed for 5 patients. Cerebrospinal fluid (CSF) noradrenaline levels showed a consistent decrease, but other biochemical parameters (CSF dopamine metabolites, platelet MAO and serum dopamine-beta-hydroxylase activities) did not change significantly. The changes of clinical symptoms and biochemical parameters did not show any correlation.
Bagdy
G
G
National Institute for Nervous and Mental Diseases, Budapest, Hungary.
Perenyi
A
A
Frecska
E
E
Seregi
A
A
Fekete
M I
MI
Tothfalusi
L
L
Magyar
K
K
Bela
A
A
Arato
M
M
D000277:Adjuvants, Pharmaceutic; D000328:Adult; D002395:Catecholamines / Q000134:cerebrospinal fluid*; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood; D011388:Prolactin / Q000097:blood; D012110:Reserpine / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D013997:Time Factors
D000277:Adjuvants, Pharmaceutic; D002395:Catecholamines; D012110:Reserpine; D011388:Prolactin; D004299:Dopamine beta-Hydroxylase; D008995:Monoamine Oxidase